Patent US4045562A successfully refreshed from Google Patents.
US4045562A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects
Assignee: Bayer Pharma AG
•
Filing: 1976-05-21
•
Granted: 1977-08-30
•
Expires: 1996-05-21
Abstract
Abstract Lisuride and its acid addition salts are effective to achieve psychic energizer effects in patients having psychic disturbances who respond poorly to the effects thereof at lower dosages at higher dosages of from 300 to 1,000 mu g.
Inventors
- 👤 Turan M. Itil
- 👤 Werner Martin Herrmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 01:18
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/48
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
127 words
A method for the treatment of psychic disturbances manifested by a. behaviorally disturbed and/or hyperkinetic children suffering from loss of concentration and memory and learning difficulties, b. adolescents and adults with so-called neurasthenic symptomatology with at least one of the following symptoms: loss of interest, loss of drive and activity, loss of energy and functional capacity, loss of concentration and learning ability, and c. geriatric patients with loss of interest, loss of drive and activity, loss of energy and functional capacity, loss of concentration and learning ability combined with severe disturbances in mental function, which comprises administering to the affected patient a daily dosage of from 300 μg. to 1,000 μg. of N-D-6-methyl-8-isoergolenyl-N',N'-diethylurea or a physiologically acceptable acid addition salt thereof effective to ameliorate the psychic disturbance.
Claim 2
Independent Claim
127 words
A method for the treatment of psychic disturbances manifested by a. behaviorally disturbed and/or hyperkinetic children suffering from loss of concentration and memory and learning difficulties, b. adolescents and adults with so-called neurasthenic symptomatology with at least one of the following symptoms: loss of interest, loss of drive and activity, loss of energy and functional capacity, loss of concentration and learning ability, and c. geriatric patients with loss of interest, loss of drive and activity, loss of energy and functional capacity, loss of concentration and learning ability combined with severe disturbances in mental function, which comprises administering to the affected patient a daily dosage of from 300 μg. to 1,000 μg. of N-D-6-methyl-8-isoergolenyl-N',N'-diethylurea or a physiologically acceptable acid addition salt thereof effective to ameliorate the psychic disturbance.
Claim 3
Dependent Claim
11 words
A method according to claim 1 wherein the administration is oral.
Claim 4
Dependent Claim
13 words
A method according to claim 1 wherein the affected patient is a geriatric.
Claim 5
Dependent Claim
16 words
A method according to claim 1 wherein the daily dosage is from 300 to 600 μg.
Claim 6
Dependent Claim
22 words
A method according to claim 1 wherein the administration is oral is divided dosages and the dosage per administration is 100-500 μg.
Claim 7
Dependent Claim
13 words
A method according to claim 5 wherein the affected patient is a geriatric.
References Cited (Backward Citations)
US3954988A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-08-29 | 1981-02-28 | 1981-08-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-08-29 | 1985-02-28 | 1985-08-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-08-29 | 1989-02-28 | 1989-08-30 | $7700.00 | Window Closed / Lapsed |